Fermentalg Launches a 10 Million Euro Capital Increase with a 20% Discount
Fermentalg announced on Tuesday the launch of a capital increase of approximately 10 million euros aimed at accelerating the commercialization of its sustainable biosolutions derived from microorganisms. The operation is supported by institutional investors and the Huvepharma group, a reference shareholder.
A Fundraising Anchored to Recent Commercial Momentum
This capital increase follows the announcement of a quarterly turnover of 3.7 million euros and the confirmation of an expected acceleration of sales in the second half of 2026, with an annual target of 20 million euros. The commercial momentum is expected to be driven particularly by the launch of two new biosolutions: a range of algal oil rich in EPA/DHA presented as an alternative to fish oils, and a natural blue dye approved by the US FDA and having received a positive opinion from the European Food Safety Authority in March 2026. The significant increase in the price of fish oils also enhances the economic competitiveness of Fermentalg's biosolutions in the agri-food sector, where industrial players are beginning a transition to natural alternatives.
Allocation of Funds and Renewed Support from Huvepharma
The net proceeds from the operation will be divided into three equal parts: accelerating commercial actions to support the expected growth, particularly in Asia and the United States; maintaining an innovation policy with the introduction of a new platform by the end of 2027; and continuing the structuring of the Company with financing of working capital needs. Subscription commitments totaling about 9 million euros have been received, including 7 million from funds managed by Vatel Capital. Huvepharma, which has invested 7.5 million euros in Fermentalg's capital and more than 10 million euros in its infrastructure since the end of 2023, commits to participate with about 2 million euros. The European leader in precision fermentation had announced at the beginning of 2026 an additional loan of 4 million euros, the amount of which will be reduced by the amount of this subscription. The price per share is set at 0.46 euros, representing a 20% discount compared to the reference price. The offer, consisting of a private placement and an offer reserved for a category of beneficiaries, began on Tuesday and is expected to close before the market opens on May 13, 2026. The settlement-delivery and admission to trading on Euronext Growth in Paris are scheduled for May 15, 2026.
